key: cord-0780873-uek1ecxf authors: Zhang, Xiaoqing; Han, Ping; Wang, Haiyong; Xu, Yanqin; Li, Fanlin; Li, Min; Fan, Lilv; Zhang, Huihui; Dai, Qiang; Lin, Hao; Qi, Xinyue; liang, Jie; Wang, Xin; Yang, Xuanming title: Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection date: 2021-05-14 journal: Mol Ther Methods Clin Dev DOI: 10.1016/j.omtm.2021.05.004 sha: e23699678d2029667c0d60a047fa0ad11a641fb3 doc_id: 780873 cord_uid: uek1ecxf The emergence of the novel human severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to the pandemic of coronavirus disease 2019 (COVID-19), which has markedly affected global health and economy. Both uncontrolled viral replication and proinflammatory cytokine storm can cause severe tissue damage in patients with COVID-19. SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as its entry receptor. In this study, we generated ACE2 extracellular domain-Fc and scFv-IL6R-Fc fusion proteins to differentially neutralize viruses and ameliorate the cytokine storm. The hACE21-740-Fc fusion protein showed a potent inhibitory effect on pseudotyped SARS-CoV-2 entry and a good safety profile in mice. In addition, scFv-IL6R-Fc strongly blocked interleukin-6 signal activation. We also established a mesenchymal stromal cell MSC-based hACE21-740-Fc and scFv-IL6R-Fc delivery system, which could serve as a potential therapy strategy for urgent clinical needs of patients with COVID-19. The clinical translation of protein-based therapeutics can be time-consuming owing to 181 good manufacturing practices (GMP) production and quality control, which may not 182 be feasible for the urgent need for treating COVID-19. Therefore, other drug delivery 183 systems should be considered to save time. MSCs have been widely used for treating 184 autoimmune diseases and as vectors for protein drug delivery. We generated an MSC 185 cell line stably expressing ACE2 1-740 -hFc (MSC-ACE2 1-740 -hFc) by lentiviral infection. As expected, this cell line persistently secreted ACE2 1-740 -hFc into the culture 187 supernatant ( Figure 5A and Figure S1 ). The concentration of ACE2 1-740 -hFc in the supernatant was about 190 ng/mL after a 4-day culture. To determine whether 189 ACE2 1-740 -hFc in MSC-derived supernatant is bio-reactive, we first measured its 190 ability to react with spike-positive 293 cells( Figure 5B ). The MSC-secreted 191 ACE2 1-740 -hFc showed a binding strength similar to that of purified ACE2 1-740 -hFc 192 ( Figure 5C ). We next investigated whether ACE2 1-740 -hFc from the MSC-derived Figure 5E ). Further, we evaluated the bio-distribution of these MSCs, 199 which were preferentially located in the lungs after 24 h of injection ( Figure 5F ). Thus, ACE2 is a carboxypeptidase that potently degrades angiotensin II to angiotensin 1-7. 37 It plays a central role in the homeostatic control of cardiorenal action. ACE2 is a 254 J o u r n a l P r e -p r o o f ACE2 is delivered to all possible tissues through the circulatory system, thereby 256 raising the concern regarding its side-effects on the cardiorenal system. Our Data are expressed as mean ± standard deviation (SD) or standard error of the mean 445 (SEM). The data of two groups were compared using a two-tailed unpaired Student's 446 t-test. Statistically significant differences p < 0.05, p < 0.01, and p < 0.001 are 447 indicated by *, **, and ***, respectively. A pneumonia outbreak associated with a new coronavirus of probable bat origin Angiotensin-converting enzyme 2 is a functional 479 receptor for the SARS coronavirus Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 Cryo-EM structure of the 2019-nCoV spike in the prefusion 485 conformation Single-cell RNA expression 487 profifiling of ACE2, the putative receptor of Wuhan Pulmonary surfactant Inhibition of SARS-CoV-2 Infections in 491 Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 Angiotensin-converting enzyme 2 is an essential 494 regulator of heart function Angiotensin-converting enzyme II in the heart and 496 the kidney Clinical Characteristics of Coronavirus Disease 2019 in China. The New England 499 journal of medicine Human recombinant soluble ACE2 in severe COVID-19 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with 610 Human neutralizing antibodies elicited by SARS-CoV-2 infection Phase I/II study of COVID-19 RNA vaccine BNT162b1 in 615 adults Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 618 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised Potently neutralizing and protective human antibodies against 622 SARS-CoV-2 The 624 Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced 628 ACE2-binding affinity High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models Mechanisms of host receptor 633 adaptation by severe acute respiratory syndrome coronavirus Generation of enzymatically competent 636 SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana Computational Design of ACE2-Based Peptide Inhibitors of 639 SARS-CoV-2 Learning from the Past: Possible Urgent 641 Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 642 2019-nCoV Optimization of 4-1BB 644 antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity Fc receptor-targeted therapies for the treatment of 62 Analysis of tissues following mesenchymal stromal cell therapy in humans 653 indicates limited long-term engraftment and no ectopic tissue formation Mesenchymal Stromal Cell 657 Therapeutic Delivery: Translational Challenges to Editorial: Safety, Efficacy and Mechanisms of 660 Action of Mesenchymal Stem Cell Therapies MSC 662 Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell 663 Product Quality and Mode of Delivery for Treatment Safety and Efficacy Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: 667 Time for New Clinical Guidelines Thromboembolism 669 Induced by Umbilical Cord Mesenchymal Stem Cell Infusion: A Report of Two Cases A) Raji and Raji-spike cells were labeled with different 701 concentrations of CFSE, and co-cultured with human primary NK cells in the 702 presence of indicated concentrations of ACE2 1-740 -hFc. ADCC effect was measured 703 by flow cytometry analysis and calculated by the ratio of Raji Raji and Raji-spike cells were labeled with different concentrations 705 of CFSE, co-cultured, and supplemented with human AB serum in the presence of 706 indicated concentrations of ACE2 1-740 -hFc. CDC effect was measured by flow 707 cytometry analysis and calculated from the ratio of Raji-spike Data represent means ± SD. Representative results of one from three (A 709 & B) repeated experiments are shown A) C57BL/6 mice received a 712 single injection of 100 µg ACE2 1-740 -hFc. The serum concentration was determined by 713 ELISA at indicated time points. (B-E) C57BL/6 mice received a single injection of 714 100 µg ACE2 1-740 -hFc. Seven days later, the hematology, body weight, and 715 hematoxylin and eosin (H&E) staining of indicated organs were analyzed. Data 716 represent means ± SEM The continuous 720 ACE2 1-740 -hFc production by stably engineered MSC-ACE2 1-740 -hFc was measured 721 by ELISA after a 1 month of culture. (B) Flow cytometry analysis of the supernatant 722 from 293 or 293-spike cells treated with MSC-ACE2 1-740 -hFc. (C) Lentiviruses 723 pseudotyped with SARS-CoV-2 spike protein were incubated with indicated dilutions 724 of MSC-ACE2 1-740 -hFc Fluorescent IRFP-positive cells were measured by flow cytometry MSC-ACE2 1-740 -hFc was intravenously injected into NSG mice, and ACE2 1-740 -hFc 727 production in the serum was determined by ELISA at indicated time points MSC-ACE2 1-740 -hFc cells were intravenously injected into NSG mice, and their 729 bio-distribution in the indicated tissues was analyzed by q-PCR. Data represent means 730 Representative results of one from three (A, C) and four (B) repeated 731 experiments are shown Figure 6. Characterization of scFv-IL6R-hFc-expressing MSCs TF-1 cells were stimulated with IL-6 in the presence of indicated concentrations 736 of scFv-IL6R-Fc and tocilizumab. Cell proliferation was determined 48 h later by 737 CCK-8 assay. (B) The continuous scFv-IL6R-Fc production from stably engineered